Danazol in Indian haemophiliacs.
Danazol, 10 mg/kg/day (maximum 600 mg/day) was given in two divided doses for 14 days in 30 patients with haemophilia-A. Rise in factor-VIII level was observed in all the patients after one week of danazol therapy, irrespective of initial factor-VIII Levels. In haemophiliacs with less than 1% factor VIII level, rise was maximum (3-6 folds); mean factor-VIII level at 7th and 14th day of danazol therapy was 2.3 +/- 0.6% and 4.8 +/- 1.1%, respectively. Only marginal increase in factor-VIII was noted in haemophiliacs with initial factor-VII levels more than 3%. The raised level of factor-VIII persisted after stopping the therapy during the observation period of 2 more weeks, irrespective of initial levels. No adverse effect was observed during or after.
Sundar
S
S
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University Varanasi, India.
Moorleedhur-Singh
G S
GS
Dube
B
B
Singh
V P
VP
Kumar
K
K
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D003613:Danazol / Q000627:therapeutic use*; D005169:Factor VIII / Q000032:analysis*; D006467:Hemophilia A / Q000188:drug therapy* / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male
D005169:Factor VIII; D003613:Danazol